SOAT1 and cancer: Soman effectively inhibited STAT phosphorylation in an ROS-independent manner, resulting in the decreased expression of glycolytic enzymes (HK2, PKM2, and LDHA) and activities of PK and LDH, leading to the suppression of aerobic glycolysis, cancer cell proliferation, and tumor growth.